Check 35,000+ stocks against 26 valuation models and 37 quality factors

Zhong Ji Longevity Science Group Ltd (0767) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of Zhong Ji Longevity Science Group Ltd HK$0.20, price HK$0.48, upside -57.5%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · HK · ISIN BMG989M11008

ZJ Thin data Sep 27, 2026

Zhong Ji Longevity Science Group Ltd

0767 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$0.2040 · Strongly overvalued (−57.5%)

!Quality 40/100

!Mixed Growth (revenue 5y +15.2 %/yr)

!Loss-making · -13.3% net margin (TTM)

!negative free cash flow

!Trails peers (2/9)

!Narrow moat 0/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear HK$0.1360 to bull HK$0.2550 Growth analysisrevenue history, year by year Quality 40/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Zhong Ji Longevity Science Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.1080 – HK$8.80 · fair‑value band HK$0.1360 – HK$0.2550 · the HK$0.4800 price screens above the HK$0.2040 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Zhong Ji Longevity Science Group in your weekly email

Every Wednesday you see whether Zhong Ji Longevity Science Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zhong Ji Longevity Science Group Limited, an investment holding company, engages in the money lending business in Hong Kong and Mainland China. It operates through Longevity Science Business; Money Lending and Financial Advisory Business; Securities and Other Investments; and Property Investment segments. The company is involved in the provision of diagnostic consultation, health and medical testing and checking, and distribution of healthcare cancer prevention and immunity healthcare supplements, as well as sales and distribution of longevity wine. It also engages in the holding of equity investments; investment in short and long-term financial assets; provision of loan financing and management services; and provision of financial and investment consulting, as well as financial advisory and management services; and investment in properties. In addition, the company offers health consulting services, and trades in medical products. Zhong Ji Longevity Science Group Limited was incorporated in 1994 and is based in Kowloon Bay, Hong Kong.

Stock analysis

Zhong Ji Longevity Science Group Ltd (0767) currently trades at HK$0.4800, while our model-based Fair Value estimate is HK$0.2040, 57.5% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 86/100, which puts the evidence level at low.

Scenario range: HK$0.1360 (bear) to HK$0.2550 (bull), the price of HK$0.4800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Zhong Ji Longevity Science Group Ltd reported revenue of HK$165M in FY2025 versus HK$63.0M in FY2021, a compound +27.3%/yr. Reported net income was −HK$16.8M in FY2025.

Key figures

Market cap HK$312M (≈ $39.8M) · P/S ratio 2.47 · EPS (TTM) HK$−0.0400 · Net margin −10.1% · Return on equity −4.0% · Return on assets (EBIT) 2.7% · Operating margin −58.9% · Revenue (TTM) HK$126M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −58%, 0767 screens richer than that median.

Fair Value models

Bear HK$0.1360 Fair Value HK$0.2040 Bull HK$0.2550

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) HK$0.3100 HK$0.4200 HK$0.6200 51

All 1 models by family

Asset-Based

NCAV (Graham) HK$0.3100 HK$0.4200 HK$0.6200 51

Open the full fair value analysis →

Notify me when 0767 reaches fair value

Put 0767 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 44 · Market factors (momentum, volatility) 36

Profitability 6

Margins and returns on capital today

Quality Growth 50

Are margins and returns improving?

Cashflow 20

Earnings quality: real cash, not paper profit

Fin. Strength 72

Balance sheet, leverage, solvency risk

Investment 98

Disciplined investing over empire-building

Low Volatility 41

Calm price path (market factor)

Momentum 34

Price trend over the last 3–12 months (market factor)

52W Momentum 34

Distance to the 52-week high (market factor)

Net Issuance 50

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−2.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+22.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.2%

Start year 2020 (pandemic). Over 10 years: +4.9% a year

Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−8.9%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−17.1% (2020) → −13.4% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

0767 screens overvalued: fair value 58% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Zhong Ji Longevity Science Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 138 stocks

Beats the industry median on 2/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 45 · Below median

Fair Value upside −57.5% · Below median

Profitability

Return on assets −3.2% · Below median

Net margin (TTM) −13.3% · Bottom 25%

Operating margin (TTM) −58.9% · Bottom 25%

Growth and dividend

Revenue growth −37.8% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.10× · Cheapest 25%

P/S (TTM) 0.32× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$675.00	$686.04	+2%
Danaher Corporation DHR	$224.49	$209.18	−7%
WuXi AppTec Co 603259	¥162.40	¥178.64	+10%
Agilent Technologies, Inc A	$172.79	$64.17	−63%
Lonza Group LONN	CHF 569.20	CHF 151.69	−73%
IQVIA Holdings IQV	$270.37	$297.41	+10%
Waters Corporation WAT	$433.54	$106.46	−75%
Illumina, Inc ILMN	$271.90	$295.60	+9%
IDEXX Laboratories, Inc IDXX	$519.26	$495.84	−5%
Mettler-Toledo International Inc MTD	$1,512	$644.24	−57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhong Ji Longevity Science Group Ltd · Fair Value
HK$0.2040 −58%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0767" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Zhong Ji Longevity Science Group Ltd · Fair Value</span><br><b style="font-size:20px">HK$0.2040</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−58%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Zhong Ji Longevity Science Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0767

Frequently asked questions

Is Zhong Ji Longevity Science Group Ltd (0767) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$0.2040 versus a price of HK$0.4800, about −58% upside (overvalued).

What is the fair value of 0767?

Our model-based fair value for Zhong Ji Longevity Science Group Ltd is HK$0.2040 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.4800.

What is the quality score of 0767?

Zhong Ji Longevity Science Group Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Zhong Ji Longevity Science Group Ltd (0767)?

Our model-based price target is the fair value of HK$0.2040 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.1360, optimistic scenario HK$0.2550. It is a calculation from audited fundamentals, not an analyst target.

What is the Zhong Ji Longevity Science Group Ltd stock forecast for 2026?

Our models put fair value at HK$0.2040, about −58% upside versus a price of HK$0.4800 (overvalued). Cautious scenario HK$0.1360, optimistic scenario HK$0.2550. The calculation is refreshed regularly with new filings.

What is the revenue of Zhong Ji Longevity Science Group Ltd (0767)?

Zhong Ji Longevity Science Group Ltd reported trailing-twelve-month revenue of about HK$126M (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Zhong Ji Longevity Science Group Ltd (0767)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhong Ji Longevity Science Group Ltd it is HK$0.2040 per share (as of Sep 27, 2026), against a price of HK$0.4800. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Zhong Ji Longevity Science Group Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 0767 trades above its calculated fair value: price HK$0.4800, fair value HK$0.2040, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0767?

No. The price is what the market pays today (HK$0.4800); the fair value is what the company's own numbers justify (HK$0.2040). For Zhong Ji Longevity Science Group Ltd the two are HK$0.2760 per share apart. That gap is exactly why we show both numbers side by side.

How much is Zhong Ji Longevity Science Group Ltd worth?

The market values Zhong Ji Longevity Science Group Ltd at about HK$312M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.4800; our models calculate a fair value of HK$0.2040 per share.

What do the bullish and bearish scenarios say about 0767?

Our models span a range for Zhong Ji Longevity Science Group Ltd: cautious scenario HK$0.1360, base HK$0.2040, optimistic HK$0.2550 per share (as of Sep 27, 2026, price HK$0.4800). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Zhong Ji Longevity Science Group Ltd (0767)?

Balance-sheet figures for Zhong Ji Longevity Science Group Ltd (as of Sep 27, 2026): return on equity −4.0%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.

How far is 0767 from its 52-week high?

Zhong Ji Longevity Science Group Ltd trades at HK$0.4800, about 23% below its 52-week high of HK$0.6200 and 45% above the low of HK$0.3300 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2040 is for.

Which stocks are comparable to Zhong Ji Longevity Science Group Ltd?

From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Zhong Ji Longevity Science Group Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$0.4800, calculated fair value HK$0.2040 (−58%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0767 calculated?

We run Zhong Ji Longevity Science Group Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.2040, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.9 % above its aggregate fair value. Zhong Ji Longevity Science Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Zhong Ji Longevity Science Group Ltd (0767)?

The closing price on Sep 29, 2026 was HK$0.4800. Our model-based fair value is HK$0.2040, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Zhong Ji Longevity Science Group Ltd right now?

The price sits above even our optimistic bull case (HK$0.2550). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.1360 to HK$0.2550) leaves room in how you read the outcome.

Key figures of Zhong Ji Longevity Science Group Ltd

How large is the market capitalisation of Zhong Ji Longevity Science Group Ltd (0767)?

The market capitalisation of Zhong Ji Longevity Science Group Ltd is HK$312M (≈ $39.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Zhong Ji Longevity Science Group Ltd (0767)?

The price-to-sales ratio of Zhong Ji Longevity Science Group Ltd is 2.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Zhong Ji Longevity Science Group Ltd (0767)?

Earnings per share at Zhong Ji Longevity Science Group Ltd are HK$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Zhong Ji Longevity Science Group Ltd (0767)?

The net margin of Zhong Ji Longevity Science Group Ltd is −10.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Zhong Ji Longevity Science Group Ltd (0767)?

The return on equity (ROE) of Zhong Ji Longevity Science Group Ltd is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Zhong Ji Longevity Science Group Ltd (0767)?

On an EBIT basis the return on assets of Zhong Ji Longevity Science Group Ltd is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Zhong Ji Longevity Science Group Ltd (0767)?

The operating margin of Zhong Ji Longevity Science Group Ltd is −58.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Zhong Ji Longevity Science Group Ltd (0767)?

Revenue at Zhong Ji Longevity Science Group Ltd is growing −37.8% versus a year earlier (3y avg +22.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Zhong Ji Longevity Science Group Ltd (0767)?

Earnings per share at Zhong Ji Longevity Science Group Ltd are growing −75.0% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Zhong Ji Longevity Science Group Ltd (0767) generate?

The free cash flow of Zhong Ji Longevity Science Group Ltd is −HK$23.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Zhong Ji Longevity Science Group Ltd (0767) hold?

Zhong Ji Longevity Science Group Ltd holds more cash than debt, HK$18.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Zhong Ji Longevity Science Group Ltd in the live analysis

One click puts Zhong Ji Longevity Science Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.